NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
Clinical Trials
6 trialsNCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT00421525 2021-08-16
Phase I/II Study of hLL1 in Multiple Myeloma
Gilead Sciences
Phase 1/2 Completed
NCT00821249 2020-10-19
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
Phase 1/2 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT00911105 2018-06-06
REVLIMID-NIS
iOMEDICO AG
Completed